Johnson Johnson Walking Away Could Boost Long-Term Value
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
GLP-1
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
41 articlesLilly Price Prediction: Case for Double-Digit Upside
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
Pfizer Could Prove Underrated GLP-1 Stock Opportunity
Pfizer may be sitting on a hidden GLP-1 opportunity. This article breaks down why the company could prove to be an un...
David Protein Says ‘Diet’ Trends Are Over, GLP-1s Upend Markets
David Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
Better Obesity Drug Race: Novo Nordisk vs Lilly 2026
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
We're Just Weeks Away: Medicare GLP-1 Coverage at $50
A new Medicare bridge program could lower GLP-1 drug bills to about $50 a month for eligible seniors. Here’s what you...
Analyst Just Declared Lilly the Clear Winner at ADA Conference
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
Deviled Eggs, Seltzer Burger Redefine the BBQ This Summer
The July 4 grilling season unfolds amid higher meat prices and a wave of GLP-1 drug use that is reshaping what househ...
UPS Expands Temperature-Controlled Storage with $48M Push
UPS is investing $48 million to add 27 temperature-controlled facilities, accelerating GLP-1 deliveries and reshaping...
Pfizer’s Obesity Pipeline Poised to Challenge Novo Nordisk
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Novo Nordisk's Wegovy Pill: Is Wall Street Missing Something Behind 3 Million Prescriptions?
A new milestone for obesity treatment arrives as Novo Nordisk's Wegovy Pill hits 3 million prescriptions. This articl...